Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) Short Interest Up 6.6% in February

kopsource · Mar 8, 2023 01:42

Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN – Get Rating) was the target of a large growth in short interest in February. As of February 15th, there was short interest totalling 5,690,000 shares, a growth of 6.6% from the January 31st total of 5,340,000 shares. Based on an average daily trading volume, of 531,500 shares, the short-interest ratio is presently 10.7 days. Currently, 12.5% of the shares of the company are sold short.

Day One Biopharmaceuticals Stock Up 6.4 %

DAWN traded up $1.18 during trading on Tuesday, reaching $19.54. The stock had a trading volume of 413,272 shares, compared to its average volume of 590,811. Day One Biopharmaceuticals has a one year low of $5.44 and a one year high of $28.35. The business has a 50-day moving average of $20.78 and a 200-day moving average of $21.02.

Get Day One Biopharmaceuticals alerts:

Analyst Upgrades and Downgrades

DAWN has been the topic of several research analyst reports. The Goldman Sachs Group upped their price target on shares of Day One Biopharmaceuticals from $45.00 to $62.00 and gave the stock a "buy" rating in a report on Monday, January 9th. Capital One Financial initiated coverage on shares of Day One Biopharmaceuticals in a report on Wednesday, February 8th. They issued an "overweight" rating and a $40.00 price target on the stock. Needham & Company LLC initiated coverage on shares of Day One Biopharmaceuticals in a report on Wednesday, December 14th. They issued a "buy" rating and a $40.00 price target on the stock. Bank of America initiated coverage on shares of Day One Biopharmaceuticals in a report on Thursday, December 1st. They issued a "buy" rating and a $34.00 price target on the stock. Finally, Piper Sandler upped their price target on shares of Day One Biopharmaceuticals from $40.00 to $45.00 and gave the stock an "overweight" rating in a report on Sunday, January 8th. One investment analyst has rated the stock with a hold rating and seven have given a buy rating to the company. Based on data from MarketBeat, the stock has a consensus rating of "Moderate Buy" and a consensus price target of $43.00.

Insider Activity at Day One Biopharmaceuticals

In other Day One Biopharmaceuticals news, insider Samuel C. Blackman sold 10,000 shares of the stock in a transaction on Tuesday, January 10th. The stock was sold at an average price of $22.86, for a total transaction of $228,600.00. Following the sale, the insider now owns 1,250,148 shares in the company, valued at $28,578,383.28. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. In other Day One Biopharmaceuticals news, Director Julie Papanek Grant sold 4,358 shares of the stock in a transaction on Thursday, December 8th. The stock was sold at an average price of $22.08, for a total transaction of $96,224.64. Following the sale, the director now owns 405,000 shares in the company, valued at $8,942,400. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, insider Samuel C. Blackman sold 10,000 shares of the stock in a transaction on Tuesday, January 10th. The stock was sold at an average price of $22.86, for a total value of $228,600.00. Following the sale, the insider now owns 1,250,148 shares in the company, valued at approximately $28,578,383.28. The disclosure for this sale can be found here. In the last ninety days, insiders sold 98,984 shares of company stock worth $2,089,505. Corporate insiders own 8.70% of the company's stock.

Institutional Inflows and Outflows

A number of institutional investors have recently added to or reduced their stakes in DAWN. Bank of New York Mellon Corp increased its stake in Day One Biopharmaceuticals by 78.3% in the first quarter. Bank of New York Mellon Corp now owns 57,490 shares of the company's stock valued at $570,000 after acquiring an additional 25,250 shares during the last quarter. MetLife Investment Management LLC purchased a new stake in Day One Biopharmaceuticals during the first quarter valued at about $154,000. Rhumbline Advisers purchased a new stake in Day One Biopharmaceuticals during the first quarter valued at about $193,000. BlackRock Inc. boosted its position in Day One Biopharmaceuticals by 54.6% during the first quarter. BlackRock Inc. now owns 1,162,916 shares of the company's stock valued at $11,537,000 after buying an additional 410,797 shares during the period. Finally, American International Group Inc. boosted its position in Day One Biopharmaceuticals by 92.7% during the first quarter. American International Group Inc. now owns 11,294 shares of the company's stock valued at $112,000 after buying an additional 5,434 shares during the period. Institutional investors own 86.08% of the company's stock.

Day One Biopharmaceuticals Company Profile

(Get Rating)

Day One Biopharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genetically defined cancers. Its lead product candidate is DAY101, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/progressive low-grade glioma.